Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)
Develop broad-spectrum products to treat various Botulinum Neurotoxin (BoNT) intoxications through milestone-driven funding in two phases.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: April 2, 2025 (Letter of Intent) | May 2, 2025 (Full Application)
Funding Amounts: R61: up to $300,000 direct costs/year (2 years) | R33: up to $750,000 direct costs/year (3 years) | Up to 5 years total
Summary: Supports milestone-driven, phased research to develop broad-spectrum therapeutics that treat and reverse intoxication by multiple botulinum neurotoxin (BoNT) serotypes.
Key Information: Clinical trials are not allowed; only U.S.-based organizations and components are eligible.
Description
This opportunity, offered by the National Institute of Allergy and Infectious Diseases (NIAID) at NIH, funds the development of improved products for treating intoxication by botulinum neurotoxins (BoNT). The focus is on broad-spectrum therapeutics that can address multiple BoNT serotypes and, crucially, reverse neuronal intoxication after exposure. The program uses a two-phase, milestone-driven R61/R33 mechanism: initial proof-of-concept and candidate selection (R61), followed by preclinical development and translation (R33). Only non-clinical research is supported; clinical trials are not allowed.
